A Phase 3, Randomized, Observer-blinded Study of JVC-001 Compared to Active-controlled in Healthy Japanese Children 1 Year of Age

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225026

Enrollment

840

Registered

2020-01-20

Start date

2020-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prophylaxis of measles, mumps, and rubella

Interventions

investigational material(s) Generic name etc : freeze-dried live attenuated measles, mumps, rubella combined vaccine INN of investigational material : - Therapeutic category code : 631 Vaccines Dosage

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese healthy children of 12 months and older and younger than 24 months

Exclusion criteria

Exclusion criteria: - Subjects with history of measles, mumps, or rubella infection - Subjects with measles, mumps, or rubella infection - Subjects with history of measles, mumps, or rubella virus vaccination

Design outcomes

Primary

Measure	Time frame
confirmatory - Seroprotection rate of anti-measles virus antibody - Seroprotection rate of anti-rubella virus antibody - Seroprotection rate of anti-mumps virus antibody	—

Secondary

Measure	Time frame
efficacy - Seroconversion rate and GMT of anti-measles virus antibody - Seroconversion rate and GMT of anti-rubella virus antibody - Seroconversion rate, seroresponse rate, and GMT of anti-mumps virus antibody	—

Countries

Japan

Contacts

Public ContactContact for Clinical Trial Information

DAIICHI SANKYO Co.,Ltd.

dsclinicaltrial_jp@daiichisankyo.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026